The HGSNAT Knockout SK-HEP-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatic adenocarcinoma cell line SK-HEP-1. This model features targeted disruption of the HGSNAT gene, which encodes a critical lysosomal enzyme responsible for acetylating terminal glucosamine residues during heparan sulfate degradation. The polyclonal format preserves the heterogeneity of the edited population, making it suitable for studying gene function in a cellular context that mirrors native tumor heterogeneity.
SK-HEP-1 cells originate from the ascitic fluid of a patient with liver adenocarcinoma and exhibit epithelial morphology with robust proliferation and a well-characterized molecular profile. This cell line serves as a versatile platform for studying hepatic cancer biology and lysosomal function, as it endogenously expresses components of the glycosaminoglycan degradation machinery, including heparanase and sulfatases. The integration of HGSNAT knockout into this background enables the dissection of lysosomal storage contributions to hepatocellular pathology.
HGSNAT encodes a lysosomal transmembrane acetyltransferase that transfers an acetyl group from acetyl-CoA to terminal glucosamine residues of heparan sulfate, a prerequisite for subsequent cleavage by N-acetylglucosamine-6-sulfatase (GNS). This reaction is a key step in the lysosomal degradation pathway of heparan sulfate, downstream of sulfatases such as iduronate-2-sulfatase and upstream of beta-glucuronidase and alpha-N-acetylglucosaminidase. HGSNAT activity is regulated by transcription factor EB (TFEB), a master controller of lysosomal biogenesis, which in turn is modulated by nutrient-sensing mTORC1 signaling. Loss of HGSNAT disrupts this coordinated process, leading to accumulation of partially degraded heparan sulfate within lysosomes, impaired autophagy flux, and lysosomal storage that drives cellular dysfunction.
In the SK-HEP-1 background, HGSNAT knockout recapitulates the biochemical hallmark of Mucopolysaccharidosis type IIIC (Sanfilippo syndrome C), a devastating lysosomal storage disorder. The accumulation of undigested heparan sulfate in these hepatic cancer cells provides a relevant model for investigating the intersection of lysosomal dysfunction and cancer cell metabolism, particularly given the emerging roles of autophagy and mTORC1 in hepatocellular carcinoma. This system allows researchers to explore how impaired catabolism alters lysosomal membrane protein composition, calcium signaling, and cross-talk with other degradation pathways, offering insights into both inherited metabolic disease and cancer-related lysosomal adaptations.
The polyclonal HGSNAT knockout population is ideally suited for functional genomics and drug discovery. Researchers can confirm HGSNAT disruption by RT-qPCR and Western blotting, assess residual enzyme activity, and quantify heparan sulfate accumulation by LC-MS, while immunostaining for lysosomal markers such as LAMP1 reveals lysosomal expansion. Autophagy flux assays using LC3 turnover and transcriptomic analysis by RNA-seq further define functional consequences and compensatory mechanisms. These assays support mechanistic studies, high-content screening, and therapeutic evaluation in a disease-relevant hepatic context. For additional product information, please contact Ascent Research.
